LAUSR

generally well controlled after switching from DFXDT to DFX-G. This finding indicates that the DFX formulation can be switched without a loss of efficacy if appropriate doses are used. The requirement for drug administration before meals is correlated with lower adherence. Meanwhile, 4 of our patients were able to receive treatment after meals after switching from DFX-DT to DFX-G, with the remaining patient choosing to retain the same administration timing in an effort to maintain treatment compliance. These findings suggested that treatment adherence was more likely to be maintained among patients who use DFX-G. However, one patient used jerry to take DFX-G because of difficulty in consuming the granule. As the number of elderly patients with MDS will increase because of societal aging, more easily consumed formulations of DFX will be needed. In conclusion, DFX-G was associated with greater satisfaction and clinically sufficient ferritin control compared with the findings for DFX-DT, and no patients required dose reduction because of safety issues. However, physicians will need to monitor the DFX dose after switching the formula.